42.7
Nükleer Yeniden Programlama Yöntemleri
View the full transcript and gain access to JoVE Core videos
Q1: What is somatic cell nuclear transfer and how does it reprogram cell fate?
Somatic cell nuclear transfer (SCNT) involves grafting a nucleus from a somatic cell into an enucleated oocyte. Transcription factors in the oocyte cytoplasm promote embryonic gene expression and trigger cell division, generating a blastocyst. The inner cell mass provides pluripotent stem cells capable of differentiating into specialized cell types, effectively reversing the original cell fate.
Q2: How does cell fusion create hybrid cells with combined traits?
Cell fusion artificially combines two different cell types using electric pulses, generating a hybrid cell displaying a combined phenotype. For example, fusing a B cell with a myeloma cell produces a hybrid capable of both indefinite proliferation and antibody production, demonstrating how fusion reprograms cellular function by merging distinct cell properties.
Q3: What are Yamanaka factors and how do they reprogram somatic cells?
Yamanaka factors—Oct-4, Sox-2, Klf-4, and c-Myc—are transcription factors highly expressed in embryonic stem cells. When delivered via retroviral vectors to somatic cells, these factors reprogram the nucleus by inducing embryonic gene expression, transforming somatic cells into induced pluripotent stem cells (iPSCs) capable of differentiating into multiple cell types.
Q4: What role do histone modifications play in nuclear reprogramming?
Histone modifications, including acetylation, methylation, and phosphorylation, enable chromatin decondensation and allow access to regulatory proteins. In SCNT, the transplanted nucleus's histone modification pattern changes to match the oocyte through oocyte-specific histone linkers like B4 and H1foo, promoting altered gene expression patterns essential for reprogramming.
Q5: How do Oct-4 and Sox-2 maintain pluripotency in reprogrammed cells?
Oct-4 (octamer-binding transcription factor 4) decides cell fate in the inner cell mass and embryonic stem cells, maintaining pluripotency during development. Sox-2 (sex-determining region Y-box 2) maintains self-renewal potential in embryonic stem cells. Together, these factors sustain the pluripotent state in induced pluripotent stem cells, enabling their differentiation into specialized cell types.
Q6: What are the clinical applications of nuclear reprogramming in regenerative medicine?
Nuclear reprogramming enables regenerative medicine by developing patient-specific cells for injury repair through stem cell therapy for tissue regeneration. Epigenetic changes transform somatic cells into pluripotent stem cells, which can differentiate into specialized cell types needed to replace damaged tissues, offering personalized therapeutic approaches without immune rejection.
Q7: What is the difference between transcription factor transduction and somatic cell nuclear transfer?
Transcription factor transduction uses retroviral vectors to deliver reprogramming genes directly into somatic cells, converting them to iPSCs without requiring an oocyte. SCNT grafts a somatic nucleus into an enucleated oocyte, relying on oocyte cytoplasmic factors for reprogramming. Both methods reverse cell fate but differ in mechanism, efficiency, and the source of reprogramming signals.